Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Constellation Energy Corporation (CEG) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance

Constellation Energy CorporationTrade
Vertex Pharmaceuticals IncorporatedTrade

Price performance (Past 24H)

Key statistics

Constellation Energy Corporation vs Vertex Pharmaceuticals Incorporated — how do they compare? Constellation Energy Corporation trades at $279.3 (market cap $98.63B), while Vertex Pharmaceuticals Incorporated trades at $529.98 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and Constellation Energy Corporation pays a 0.61% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.

CEGVRTX
Market Cap
$98.63B$134.25B
Sector
EnergyHealth
52-Week High
$403.95$529.65
52-Week Low
$236.50$376.62
Enterprise Value
$122.63B$128.37B
Dividend Yield
0.61%

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Constellation Energy Corporation

Constellation is the largest producer of carbon-free energy in the U.S. and a leading nuclear power plant operator. It provides sustainable electricity to millions of residential, public, and industrial customers.

Read more on CEG

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Read more on VRTX